Skip to main content

T2 Biosystems, Inc.

TTOODelisted Jul 10, 2025
Industry
Surgical & Medical Instruments & Apparatus
SEC CIK
0001492674

T2 Biosystems, Inc. was delisted on Jul 10, 2025; its insiders filed their last Form 4 on Jan 2, 2025; 1 institution reported holding it in 13F filings for Q2 2025, worth $0 in total; no superinvestor held it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by T2 Biosystems, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for T2 Biosystems, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for T2 Biosystems, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Cumming John WDirector5,256Jan 2, 20250
Liebman SeymourDirector7,002Jan 2, 20250
Elsbree David BDirector23Jan 2, 20250
Sperzel John J IIISee Remarks400Jan 2, 20250
Gibbs Michael TerrenceGeneral Counsel135Jan 2, 20250
Sprague John MCFO141Jan 2, 20250
Saunders NinfaDirector7,322Jan 2, 20250
Toft RobinDirector5,772Jan 2, 20250
Adams Laura LeeDirector37Jan 2, 20250
Giffin Brett A.Chief Commercial Officer77Jan 2, 20250
CRG Partners III L.P.10% Owner4,704,729IndirectMay 13, 20240
CRG Partners III - Parallel Fund (A) L.P.10% Owner4,704,729IndirectMay 13, 20240
CR Group L.P.10% Owner4,704,729IndirectMay 13, 20240
CRG Partners III - Parallel Fund B (Cayman) L.P.10% Owner4,704,729IndirectMay 13, 20240
CRG Partners III (Cayman) Lev AIV I L.P.10% Owner4,704,729IndirectMay 13, 20240
CRG Partners III (Cayman) Unlev AIV I L.P.10% Owner4,704,729IndirectMay 13, 20240
Bernard ThierryDirector7,322Oct 11, 20230
Barclay AlecChief Operations Officer181,945Apr 11, 20220
Ahuja AparnaChief Medical Officer107,611Feb 23, 20220
Goldman Sachs & Co. LLC10% Owner4,201,582IndirectAug 3, 20210
Goldman Sachs Group Inc10% Owner4,201,582IndirectAug 3, 20210
Jones Adrian MDirector4,201,582IndirectAug 3, 20210
McDonough JohnDirector516,386Jul 2, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 17, 2024 (view filing)Sep 134 daysElsbree David BDirectorSSale−55$2.42−$133.1−70.5%23 after
Nov 28, 2023 (view filing)Feb 20281 daysGiffin Brett A.Chief Commercial OfficerSSale−537$0.65−$349.05−15.0%3.05K afterAmended
Sep 29, 2023 (view filing)4:30 PM ETSep 27-282 daysCRG Partners III L.P. and 4 others10% OwnerSSale−13.1M$0.173−$2.27M−100.0%0 after8 lots
Sep 28, 2023 (view filing)4:30 PM ETSep 262 daysCRG Partners III L.P. and 4 others10% OwnerSSale−5.39M$0.2007−$1.08M−60.2%3.56M after4 lots
Sep 27, 2023 (view filing)5:53 PM ETSep 252 daysCRG Partners III L.P. and 4 others10% OwnerSSale−250.0K$0.25−$62.5K−4.7%5.02M after4 lots
Sep 26, 2023 (view filing)5:15 PM ETSep 224 daysCRG Partners III L.P. and 4 others10% OwnerSSale−5.08M$0.2588−$1.31M−50.0%5.09M after4 lots
Sep 25, 2023 (view filing)8:30 PM ETSep 214 daysCRG Partners III L.P. and 4 others10% OwnerSSale−6.34M$0.3005−$1.90M−49.5%6.47M after4 lots
Sep 22, 2023 (view filing)4:15 PM ETSep 202 daysCRG Partners III L.P. and 4 others10% OwnerSSale−7.75M$0.3106−$2.41M−48.7%8.18M after4 lots
Sep 21, 2023 (view filing)4:30 PM ETSep 192 daysCRG Partners III L.P. and 4 others10% OwnerSSale−10.4M$0.366−$3.81M−50.3%10.3M after4 lots
Apr 6, 2023 (view filing)1:08 PM ETMar 289 daysLateGibbs Michael TerrenceGeneral CounselSSale−239$0.481−$114.96−3.5%6.61K after
Mar 9, 2023 (view filing)Feb 22-2815 daysLateSprague John MChief Financial OfficerSSale−2.69K$0.6244−$1.68K−27.0%7.27K after2 lots
Mar 9, 2023 (view filing)Feb 22-2815 daysLateGibbs Michael TerrenceGeneral CounselSSale−3.73K$0.6245−$2.33K−36.4%6.52K after2 lots
Mar 9, 2023 (view filing)Feb 22-2815 daysLateSperzel John J IIIChairman and CEOSSale−9.77K$0.6322−$6.18K−36.1%17.3K after2 lots
Nov 22, 2022 (view filing)Nov 1012 daysLateGiffin Brett A.Chief Commercial OfficerSSale−1.29K$1.79−$2.31K−36.4%2.25K after
Apr 11, 2022 (view filing)9:50 AM ETApr 74 daysGibbs Michael TerrenceGeneral CounselPPurchase+10.0K$0.49+$4.90K+6.4%166.7K after
Apr 11, 2022 (view filing)9:40 AM ETApr 83 daysSprague John MChief Financial OfficerPPurchase+10.0K$0.4767+$4.77K+7.0%152.3K after
Apr 11, 2022 (view filing)9:38 AM ETApr 83 daysGiffin Brett A.Chief Commercial OfficerPPurchase+10.6K$0.489+$5.18KNew position10.6K after
Apr 11, 2022 (view filing)Apr 74 daysSperzel John J IIIChairman, CEO, and PresidentPPurchase+30.0K$0.50+$15.0K+15.6%221.8K after
Apr 11, 2022 (view filing)Apr 83 daysBarclay AlecChief Operations OfficerPPurchase+13.0K$0.50+$6.48K+7.7%181.9K after
Jan 10, 2022 (view filing)4:19 PM ETJan 64 daysAhuja AparnaChief Medical OfficerSSale−62.0K$0.48−$29.8K−36.5%107.6K after
Aug 3, 2021 (view filing)6:41 PM ETMar 24-May 20, 2020497 daysLateGoldman Sachs & Co. LLC and 1 other10% OwnerPPurchase+46.3K$0.6437+$29.8K+1.1%4.20M after7 lotsDuplicate filing
Aug 3, 2021 (view filing)6:41 PM ETMar 24-May 19, 2020497 daysLateGoldman Sachs & Co. LLC and 1 other10% OwnerSSale−41.1K$0.6238−$25.7K−1.0%4.20M after23 lotsDuplicate filing
Aug 3, 2021 (view filing)6:39 PM ETMar 24-May 20, 2020497 daysLateJones Adrian MDirectorPPurchase+46.3K$0.6437+$29.8K+1.1%4.20M after7 lots
Aug 3, 2021 (view filing)6:39 PM ETMar 24-May 19, 2020497 daysLateJones Adrian MDirectorSSale−41.1K$0.6238−$25.7K−1.0%4.20M after23 lots
Jul 2, 2021 (view filing)Jul 11 dayMcDonough JohnDirectorSSale−18.2K$1.16−$21.1K−3.4%516.4K after
Jul 2, 2021 (view filing)Jul 11 dayCumming John WDirectorSSale−18.2K$1.16−$21.1K−26.3%50.9K after